{"success":true,"data":{"pressRelease":{"id":"23343","rtpr_id":"nPnbXb21ha","ticker":"QGEN","exchange":"NYSE","all_tickers":["QGEN","QIA"],"title":"Qiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)","author":"PR Newswire","published_at":"2026-05-06T13:00:12.523Z","article_body":"Qiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)\n\nPR Newswire\n\nNEW YORK, May 6, 2026\n\nQiagen projected a low single digit rate first-quarter QuantiFERON growth rate\non February 5, 2026. Actual Q1 2026 volumes showed a 5% decline\n\nNEW YORK, May 6, 2026 /PRNewswire/ -- Qiagen N.V. (NYSE: QGEN) shares fell\nmore than 10.5% after the company disclosed QuantiFERON faltered on\n\"significantly lower immigration testing demand.\" Shareholders who lost money\non Qiagen are encouraged to submit their information to discuss their legal\nrights\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681734-5&h=1468590125&u=https%3A%2F%2Fzlk.com%2Fcases%2Fqiagen-n-v-lawsuit-submission-form%3Fprid%3D186048%26wire%3D4&a=+submit+their+information+to+discuss+their+legal+rights+)\n. You may also contact Joseph E. Levi, Esq. via email at\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)  or by telephone at\n(212) 363-7500.\n\n(https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.html)\n\nDuring the previous earnings call on February 5, 2026, CEO Thierry Bernard was\nconfident: \"You will see QuantiFERON picking up in Q2 … accelerating to\nachieve … between 6% and 7% growth\" in 2026. He noted Qiagen's projections\nremained \"perfectly aligned with the target that we gave during our Capital\nMarket Day in June '24.\"\n\nOn April 28, 2026, Qiagen walked back on these claims and CFO Roland Sackers\nrevealed the disappointing guidance: sales were now projected to \"continue at\na largely unchanged level from the second quarter of '25,\" and investors would\nhave to wait for QuantiFERON to \"return[] to a more normalized growth rate in\n'27.\"\n\nIf you purchased Qiagen securities and suffered a loss, click here to discuss\nyour legal options with Levi & Korsinsky\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681734-5&h=3288967088&u=https%3A%2F%2Fzlk.com%2Fcases%2Fqiagen-n-v-lawsuit-submission-form%3Fprid%3D186048%26wire%3D4&a=+click+here+to+discuss+your+legal+options+with+Levi+%26+Korsinsky+)\n. You may also contact Joseph E. Levi, Esq. via email at\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)  or by telephone at\n(212) 363-7500.\n\nWHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services'\nTop 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a\nnationally recognized leader in shareholder rights litigation. With a team of\nover 70 professionals, the firm has recovered hundreds of millions of dollars\nfor investors.\n\nFrequently Asked Questions About the QGEN Investigation\n\nQ: Who is eligible to participate in the QGEN investigation?  A: Investors\nwho suffered financial losses due to the stock's significant drop on April 28,\n2026, even if you sold your shares after the stock declined.\n\nQ: What specific misstatements are being investigated?  A: The QGEN\ninvestigation concerns statements made by the company and its management\nregarding its sales-growth outlook, QuantiFERON TB test demand, its debt\nclassification, and the adequacy of its non-GAAP financial disclosures during\nthe class period. When the true state was revealed, the stock price declined\nsharply.\n\nQ: What documents do I need to make a claim?  A: Brokerage statements or\ntrade confirmations showing purchase dates, share quantities, prices paid, and\nany subsequent sale dates and prices.\n\nQ: What happens after I contact Levi & Korsinsky?  A: An attorney will\nreview your trading history at no cost and provide an initial assessment of\nyour potential recovery.\n\nQ: What if I already sold my QGEN shares -- can I still recover losses?  A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the determined class period and sold at a\nloss may still participate.\n\nQ: What does it cost me to participate?  A: Nothing. Securities\ninvestigations and the potential resultant class actions are handled on a pure\ncontingency basis. No upfront fees, no retainer, no out-of-pocket costs.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)\nTel: (212) 363-7500\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/qiagen-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-qiagen-nv-qgen-302763808.html\n(https://www.prnewswire.com/news-releases/qiagen-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-qiagen-nv-qgen-302763808.html)\n\nSOURCE Levi & Korsinsky, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbXb21ha","title":"Qiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)","author":"PR Newswire","ticker":"QGEN","created":"2026-05-06T13:00:12.523Z","tickers":["QGEN","QIA"],"exchange":"NYSE","article_body":"Qiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)\n\nPR Newswire\n\nNEW YORK, May 6, 2026\n\nQiagen projected a low single digit rate first-quarter QuantiFERON growth rate\non February 5, 2026. Actual Q1 2026 volumes showed a 5% decline\n\nNEW YORK, May 6, 2026 /PRNewswire/ -- Qiagen N.V. (NYSE: QGEN) shares fell\nmore than 10.5% after the company disclosed QuantiFERON faltered on\n\"significantly lower immigration testing demand.\" Shareholders who lost money\non Qiagen are encouraged to submit their information to discuss their legal\nrights\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681734-5&h=1468590125&u=https%3A%2F%2Fzlk.com%2Fcases%2Fqiagen-n-v-lawsuit-submission-form%3Fprid%3D186048%26wire%3D4&a=+submit+their+information+to+discuss+their+legal+rights+)\n. You may also contact Joseph E. Levi, Esq. via email at\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)  or by telephone at\n(212) 363-7500.\n\n(https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.html)\n\nDuring the previous earnings call on February 5, 2026, CEO Thierry Bernard was\nconfident: \"You will see QuantiFERON picking up in Q2 … accelerating to\nachieve … between 6% and 7% growth\" in 2026. He noted Qiagen's projections\nremained \"perfectly aligned with the target that we gave during our Capital\nMarket Day in June '24.\"\n\nOn April 28, 2026, Qiagen walked back on these claims and CFO Roland Sackers\nrevealed the disappointing guidance: sales were now projected to \"continue at\na largely unchanged level from the second quarter of '25,\" and investors would\nhave to wait for QuantiFERON to \"return[] to a more normalized growth rate in\n'27.\"\n\nIf you purchased Qiagen securities and suffered a loss, click here to discuss\nyour legal options with Levi & Korsinsky\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4681734-5&h=3288967088&u=https%3A%2F%2Fzlk.com%2Fcases%2Fqiagen-n-v-lawsuit-submission-form%3Fprid%3D186048%26wire%3D4&a=+click+here+to+discuss+your+legal+options+with+Levi+%26+Korsinsky+)\n. You may also contact Joseph E. Levi, Esq. via email at\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)  or by telephone at\n(212) 363-7500.\n\nWHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services'\nTop 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a\nnationally recognized leader in shareholder rights litigation. With a team of\nover 70 professionals, the firm has recovered hundreds of millions of dollars\nfor investors.\n\nFrequently Asked Questions About the QGEN Investigation\n\nQ: Who is eligible to participate in the QGEN investigation?  A: Investors\nwho suffered financial losses due to the stock's significant drop on April 28,\n2026, even if you sold your shares after the stock declined.\n\nQ: What specific misstatements are being investigated?  A: The QGEN\ninvestigation concerns statements made by the company and its management\nregarding its sales-growth outlook, QuantiFERON TB test demand, its debt\nclassification, and the adequacy of its non-GAAP financial disclosures during\nthe class period. When the true state was revealed, the stock price declined\nsharply.\n\nQ: What documents do I need to make a claim?  A: Brokerage statements or\ntrade confirmations showing purchase dates, share quantities, prices paid, and\nany subsequent sale dates and prices.\n\nQ: What happens after I contact Levi & Korsinsky?  A: An attorney will\nreview your trading history at no cost and provide an initial assessment of\nyour potential recovery.\n\nQ: What if I already sold my QGEN shares -- can I still recover losses?  A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the determined class period and sold at a\nloss may still participate.\n\nQ: What does it cost me to participate?  A: Nothing. Securities\ninvestigations and the potential resultant class actions are handled on a pure\ncontingency basis. No upfront fees, no retainer, no out-of-pocket costs.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com (mailto:jlevi@levikorsinsky.com)\nTel: (212) 363-7500\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/qiagen-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-qiagen-nv-qgen-302763808.html\n(https://www.prnewswire.com/news-releases/qiagen-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-qiagen-nv-qgen-302763808.html)\n\nSOURCE Levi & Korsinsky, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-06T13:00:12.583366176Z","server_sent_at_ms":1778072412583},"received_at":"2026-05-06T13:00:12.635Z","source_url":null},"analysis":{"id":"18008","press_release_id":"23343","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Levi & Korsinsky announced an investigation into the officers and directors of Qiagen N.V., encouraging investors who suffered losses to contact the firm.\n\nThe law firm cites discrepancies between management's optimistic statements on February 5 regarding QuantiFERON growth and the subsequent disclosure of significantly lower demand on April 28.\n\nThis release is a plaintiff-firm solicitation for a class action, not an issuer disclosure, and offers legal representation on a contingency basis.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Attorney"},{"name":"Ed Korsinsky","role":"Attorney"},{"name":"Thierry Bernard","role":"CEO"},{"name":"Roland Sackers","role":"CFO"}],"products":["QuantiFERON"],"companies":[{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"Qiagen N.V.","ticker":"QGEN","relationship":"target"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Levi & Korsinsky. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"QGEN"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky announced an investigation into the officers and directors of Qiagen N.V., encouraging investors who suffered losses to contact the firm.\n\nThe law firm cites discrepancies between management's optimistic statements on February 5 regarding QuantiFERON growth and the subsequent disclosure of significantly lower demand on April 28.\n\nThis release is a plaintiff-firm solicitation for a class action, not an issuer disclosure, and offers legal representation on a contingency basis.","key_figures":{},"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Attorney"},{"name":"Ed Korsinsky","role":"Attorney"},{"name":"Thierry Bernard","role":"CEO"},{"name":"Roland Sackers","role":"CFO"}],"products":["QuantiFERON"],"companies":[{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"Qiagen N.V.","ticker":"QGEN","relationship":"target"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-06T22:58:29.296Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":null,"modelName":"glm-4.7"}}